Global Smoking Cessation Aids Market is Segmented By Product(Nicotine Replacement Therapy and Medication), By Distribution Channel(Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029
Smoking Cessation Aids Market Overview
The global smoking cessation aids market is estimated to reach at a CAGR of 16.9% during the forecast period (2022-2029).
Tobacco use can lead to tobacco/nicotine dependence and serious health problems. Quitting smoking greatly decreases the risk of developing smoking-related diseases. Tobacco/nicotine dependence is a condition that often requires repeated treatments, but there are helpful treatments and resources for quitting. Tobacco smoke contains a deadly mix of more than 7,000 chemicals, of which hundreds are harmful, and about 70 can cause cancer. Smoking increases, therefore, increases the risk of serious health problems, many diseases, and death. People who stop smoking greatly reduce their risk of disease and early death.
Source: DataM Intelligence Analysis (2021)
Smoking Cessation Aids Market Dynamics
The global smoking cessation aids market growth is driven by the rising addiction toward tobacco smoking, increasing number of campaigns to reduce smoking and tobacco dependence are some of the factors driving the market growth.
Rising awareness about smoking cessation therapy is expected to drive the market growth
Smoking is one of the major causes of lung cancer and other respiratory and cardiac diseases. Awareness about these health hazards has influenced individuals to adopt smoking cessation therapy. The awareness among the individuals is through digital media, print media, and other sources of information have proved to be effective in curbing the nicotine addiction crisis to some extent.
Cigarette smoking remains the leading cause of preventable disease, disability, and death. According to the Centers for Disease Control and Prevention (CDC), In 2019, nearly 14 of every 100 U.S. adults aged 18 years or older (14.0%) smoked cigarettes. This hints at a high usage of de-addiction products. Also, this depicts the growing awareness of the people and their readiness to quit smoking. There are also non-government and government establishments are working to educate and help people quit smoking that is engaged dedicatedly to bring the number of smokers down. For instance, in 2017, the U.S. Food and Drug Administration launched an adult smoking cessation education campaign to encourage cigarette smokers to quit smoking.
The rising addiction to tobacco smoking is expected to drive the market growth
Nicotine is a highly addictive substance found in the tobacco plant. Smoking tobacco is proven to be dangerous in all forms as it can lead to chronic health conditions, preventable diseases, deaths, and disabilities. According to the Centers for Disease Control and Prevention (CDC), in 2018, nearly 40 million adults in the US smoked cigarettes. Moreover, about 4.7 million middle and high-school students used at least one tobacco product, and around 1,600 young population below the age of 18 in the US smoked their first cigarettes. Every year, nearly half a million patients die due to illness caused by smoking. The US government spends ~US$ 225 billion for medical care to treat patients suffering from smoking-associated conditions. Therefore, the prevalence of tobacco smoking is high across various countries in the world.
High cost associated with smoking cessation is likely to hamper the market growth
Smoking cessation has been called the gold standard of healthcare cost-effectiveness, producing additional years of life at costs. Despite their cost-effectiveness, smoking cessation services are not covered by many healthcare providers. According to the Centers for Disease Control and Prevention (CDC), if smoking cessation yields 1.2 years additional life, the cessation services cost $5170 per life-year, and cessation services and mental health care cost $9580 per life-year. Every year, smoking kills approximately 480,000 people in the US. It costs the nation more than $300 billion a year, including more than $225 billion in direct medical care and more than $156 billion in lost productivity, imposing a heavy economic burden on employers, health plans, and federal, state, and local governments. Hence, these factors are expected to hamper market growth.
COVID-19 Impact Analysis On Smoking Cessation Aids Market
Even though COVID-19, a respiratory infection, killed more people than any other infectious disease in 2020, cigarette smokers have continued to smoke despite the known risk of respiratory disease and the many other health threats that smoking brings. Smoking is the number one preventable cause of death in the U.S. The pandemic has hit so hard that a decades-long decline in cigarette sales completely stopped last year. People with mental health and substance abuse disorders are especially at risk.
A report from the North American Quitline Consortium released in 2021 confirms a drastic decline in requests for stop-smoking services. Smoking increases the risk of developing symptomatic COVID-19 and having more severe illness if the disease is contracted. In part, this may be due to smoking’s harmful effects on the immune system, making the body less successful in fighting disease. It is more important than ever to make smokers aware of their increased risk for severe illness with COVID-19 and the availability of tobacco cessation programs that can help them quit. Messaging on the importance of smoking cessation during the pandemic needs to be amplified. By increasing efforts to implement such messaging while offering effective tobacco cessation services, public health and health care professionals can ensure that the health gains from tobacco cessation continue. The COVID-19 pandemic has challenged progress on smoking cessation in 2020, but this does not need to be the case in 2021.
Smoking Cessation Aids Market Segment Analysis
The E-cigarettes segment is expected to hold the largest share in this market segment
E-cigarettes are considered a healthy alternative to tobacco cigarettes and are estimated to be the fastest-growing segment over the forecast period. E-cigarettes are an effective alternative for reducing health conditions associated with tobacco, while nicotine replacement therapies work best for smoking cessation. E-cigarettes are a potential threat to tobacco-based cigarettes.
At the same time, an opportunity for tobacco manufacturers to enter the new emerging segment catering to the smoking population. Consumption of e-cigarettes is less harmful than regular cigarettes, no smoke and no risk of passive smoking, allowed to use even in no-smoking places, varying nicotine levels, and availability in various flavors are some of the major driving factors for the e-cigarettes market. In addition, the increasing popularity of e-cigarettes backed by their electronic feature is considered to be the major factor contributing towards its increasing demand.
Source: DataM Intelligence Analysis (2021)
Smoking Cessation Aids Market Geographical Analysis
Asia-Pacific region holds the largest market share of the global smoking cessation aids market
Asia-Pacific is expected to be the fastest-growing market due to increasing awareness about smoking cessation and nicotine de-addiction products and a huge population base in the area. In a study called Tobacco Smoking and Mortality in Asia published by JAMA Network March 2019, a pooled meta-analysis, an international collaboration of researchers, led by those from Vanderbilt University, United States, has studied the trends in tobacco use in China, Japan, South Korea, Singapore, Taiwan, and India. It was estimated that 8.3 million deaths will be attributed to smoking by 2030, half of the world's male smokers live in China, India, and Indonesia and Asia is the world's largest tobacco consumer and producer.
Source: DataM Intelligence Analysis (2021)
Smoking Cessation Aids Market Competitive Landscape
The global smoking cessation aids market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Takeda Pharmaceutical Company Limited, NJOY, Pfizer Inc, Cipla Ltd, GlaxoSmithKline Plc, Dr Reddy's Laboratories, Juul Labs, Glenmark, Perrigo Company plc, Johnson and Johnson Services, Inc and Imperial Brands.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in July 2020, Dr Reddy's Laboratories launched OTC Nicotine Polacrilex Lozenges in the United States. The Nicotine lozenges brands and store brand markets witnessed United States retail sales of about USD 200 million in 2020. The product is a significant addition to the company’s offering of Nicotine Replacement Therapy.
Global Smoking Cessation Aids Market – Market Key Companies to Watch
Cipla Ltd
Overview: Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India. Founded in 1935 with employees around 25,000+. Cipla primarily offers its products through generics and branded generics, speciality and consumer health. It operates through Australia, Europe, Kenya, Malaysia, Morocco, Nepal, South Africa, Sri Lanka, Uganda, the United Kingdom and the USA.
Product Portfolio: It includes products like Nicotex Patch, Nicotex Gums.
Product: A Nicotex Patch is a transdermal/skin patch that helps to quit smoking using the principle of Nicotine Replacement Therapy (NRT). The patch when placed on the body gradually releases nicotine throughout the day.
Why Purchase the Report?
- Visualize the composition of the global smoking cessation aids market segmentation by product, distribution channel and region highlighting the key commercial assets and players.
- Identify commercial opportunities in the global smoking cessation aids market by analyzing trends and co-development deals.
- Excel data sheet with thousands of data points of global smoking cessation aids market-level 4/5 segmentation.
- PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
- Product mapping in excel for the key product of all major market players
The global smoking cessation aids market report would provide access to an approx. 40+ market data table, 45+ figures and 180 pages.
